← Back to Search

Other

Personalized Treatment Using DST for Cancer

N/A
Recruiting
Led By Jorge Manrique-Succar, MD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up tp 1 year post-treatment
Awards & highlights

Study Summary

This trial aims to provide personalised treatment for advanced cancer, reducing the risk of relapse and resistance to chemotherapy. #cancer #personalizedmedicine

Who is the study for?
This trial is for adults over 18 with recurrent or refractory cancer who've tried at least two previous therapies. They must be willing to provide consent, have a recent biopsy or bone marrow sample, and agree to genetic testing. It's not for those with new, highly curable cancers or insufficient tissue samples.Check my eligibility
What is being tested?
The study tests an individualized treatment approach using Drug Sensitivity Tests (DST) on participants' tumor samples to find the most effective therapy tailored to their specific cancer profile.See study design
What are the potential side effects?
Since this trial involves various treatments based on individual test results, side effects will vary widely among participants depending on which drugs are identified as potentially beneficial for their unique cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment recommendation feasibility
Secondary outcome measures
Progression-free survival
Progression-free survival ratio
Treatment responsiveness

Trial Design

1Treatment groups
Experimental Treatment
Group I: Drug Sensitivity TestingExperimental Treatment1 Intervention
The results of the DST and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices. The physician will decide which treatment will be most appropriate for each case. All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available.

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
453 Previous Clinical Trials
31,894 Total Patients Enrolled
Florida International UniversityOTHER
100 Previous Clinical Trials
17,519 Total Patients Enrolled
Community Foundation of BrowardUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any new participants being welcomed into this experiment?

"The clinicaltrials.gov repository indicates that this medical trial is not accepting participants at present; it was initially posted on January 1st, 2024 and last adjusted on September 1st, 2023. However, there are 26 other studies actively attempting to enrol patients in the meantime."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Individualized Treatments in Adults With Relapsed/Refractory Cancers
2023. "Individualized Treatments in Adults With Relapsed/Refractory Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06024603.
~24 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top